Market Data
Market Cap₹49.03 Cr.
52W High₹35.52
Current Price₹20.68
52W Low₹15.5
Down from 52W High41.8 %
Face Value₹10
Performance
ROCE30.11 %
ROE25.62 %
EPS (TTM)₹0.9
EPS Prev Qtr₹0.45
EPS Last Year₹0.77
EBITDA Qtr₹2.77 Cr.
Book Value₹12
Financial Health
Debt/Equity0.02
Debt/Profit0.08
Total Assets₹86.27 Cr.
Earning Power9.9 %
Valuation
Stock P/E6.46
Industry P/E33.3
Price to Book1.66
Price to Sales0.37
Graham Number₹29.95
Key Metrics
__derived
1
Face Value
₹10
About Kabra Drugs Ltd
Healthcare · Pharmaceuticals
Kabra Drugs Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹49.03 Cr.
Price Chart
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue grew 546.4% YoY, Profit grew 524.0% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 7.15 | 19.76 | 30.42 | 35.41 | 46.22 |
| ↳ QoQ Growth | - | +176.4% | +53.9% | +16.4% | +30.5% |
| Expenses | 7.66 | 17.74 | 28 | 34.08 | 43.45 |
| Operating Profit | -0.52 | 2.03 | 2.42 | 1.32 | 2.77 |
| OPM % | -7.27% | 10.27% | 7.96% | 3.73% | 5.99% |
| Other Income | 0.01 | 0.18 | 0.18 | 0.11 | 0.08 |
| Interest | 0 | 0 | 0 | 0.01 | 0.01 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 |
| EBITDA | -0.51 | 2.04 | 2.43 | 1.34 | 2.79 |
| EBITDA Margin % | -7.13% | 10.32% | 7.99% | 3.78% | 6.04% |
| Profit Before Tax | -0.5 | 2.21 | 2.6 | 1.42 | 2.84 |
| Tax % | 0% | 16.74% | 1.15% | 25.35% | 25.35% |
| Net Profit | -0.5 | 1.84 | 2.57 | 1.06 | 2.12 |
| ↳ QoQ Growth | - | +468.0% | +39.7% | -58.8% | +100.0% |
| EPS | -0.21 | 0.77 | 1.08 | 0.45 | 0.9 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 92.74 | 131.81 |
| Expenses | 87.48 | 123.27 |
| Operating Profit | 5.25 | 8.54 |
| OPM % | 5.66% | 6.48% |
| Other Income | 0.48 | 0.55 |
| Interest | 0.01 | 0.02 |
| Depreciation | 0.05 | 0.06 |
| Profit Before Tax | 5.73 | 9.07 |
| Tax % | 13.26% | 16.32% |
| Net Profit | 4.97 | 7.59 |
| EPS | 2.09 | 3.2 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
16.9%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
30.79%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 23.7079 | 23.71 |
| Reserves | 0.9468 | 5.91 |
| Borrowings | 0.44 | 0.57 |
| Other Liabilities | 0.13 | 56.08 |
| Total Liabilities | 25.229 | 86.27 |
| Fixed Assets | 0.0439 | 0.84 |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| Other Assets | 25.19 | 85.43 |
| Total Assets | 25.229 | 86.27 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | -4.7068 |
| Cash from Investing Activity | -0.0513 |
| Cash from Financing Activity | 23.3864 |
| Net Cash Flow | 18.6283 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 337.29 |
| ROCE % | 6.13% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 0% | 0% | 0% | 0% |
| FIIs % | 0% | 0% | 0% | 0% |
| DIIs % | 0% | 0% | 0% | 0% |
| Public % | 95% | 91.43% | 90.92% | 90.69% |
| No. of Shareholders | 8,098 | 8,862 | 9,185 | 9,680 |